Eiger Biopharmaceuticals (EIGR) PT Set at $26.00 by Oppenheimer

Oppenheimer set a $26.00 target price on Eiger Biopharmaceuticals (NASDAQ:EIGR) in a research note published on Thursday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other research analysts have also recently commented on EIGR. LADENBURG THALM/SH SH set a $28.00 price target on Eiger Biopharmaceuticals and gave the stock a buy rating in a report on Wednesday. Zacks Investment Research cut Eiger Biopharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 31st. ValuEngine cut Eiger Biopharmaceuticals from a strong-buy rating to a buy rating in a report on Monday, October 8th. Finally, Wedbush set a $53.00 price target on Eiger Biopharmaceuticals and gave the stock a buy rating in a report on Monday, August 13th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $30.38.

Shares of EIGR stock traded down $0.24 during trading hours on Thursday, reaching $11.78. 2,104 shares of the company traded hands, compared to its average volume of 102,498. Eiger Biopharmaceuticals has a 12-month low of $7.46 and a 12-month high of $18.00. The company has a quick ratio of 8.49, a current ratio of 8.49 and a debt-to-equity ratio of 0.35. The stock has a market cap of $166.23 million, a P/E ratio of -2.46 and a beta of 1.81.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings data on Friday, August 10th. The biotechnology company reported ($0.82) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.82). On average, equities research analysts expect that Eiger Biopharmaceuticals will post -2.98 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GMT Capital Corp purchased a new position in Eiger Biopharmaceuticals in the 2nd quarter worth approximately $3,459,000. Ardsley Advisory Partners purchased a new position in Eiger Biopharmaceuticals in the 2nd quarter worth approximately $305,000. 683 Capital Management LLC lifted its holdings in Eiger Biopharmaceuticals by 51.2% in the 2nd quarter. 683 Capital Management LLC now owns 295,285 shares of the biotechnology company’s stock worth $3,602,000 after purchasing an additional 100,000 shares in the last quarter. Northern Trust Corp lifted its holdings in Eiger Biopharmaceuticals by 169.7% in the 1st quarter. Northern Trust Corp now owns 29,376 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 18,483 shares in the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of Eiger Biopharmaceuticals by 171.2% during the 2nd quarter. Acadian Asset Management LLC now owns 56,266 shares of the biotechnology company’s stock worth $687,000 after acquiring an additional 35,518 shares in the last quarter. 69.28% of the stock is currently owned by institutional investors.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Further Reading: Fundamental Analysis and Individual Investors

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply